CLDN6 and ovarian cancer: Notably, the ORR in patients treated with 0.2–3.0 mg/kg doses of ixotatug vedotin was 33% (21/64), and the ORRs in CLDN6-positive platinum-resistant ovarian cancer patients with 2.4 or 3.0 mg/kg ixotatug vedotin were 50% and 42%, respectively (Konecny et al., 2024).